Welcome to our dedicated page for Generation Bio Co. SEC filings (Ticker: GBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Generation Bio Co. (NASDAQ: GBIO), a biotechnology company based in Cambridge, Massachusetts that focuses on T cell-driven autoimmune diseases. These regulatory documents provide detailed information on the company’s operations, financial condition, governance and transaction activity.
Generation Bio’s current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe quarterly financial results, including cash, cash equivalents and marketable securities, research and development expenses, general and administrative expenses and net loss. Other 8-Ks outline leadership changes, consulting arrangements with senior executives and lease-related matters.
A key 8-K filed on December 15, 2025 discloses an Agreement and Plan of Merger with XOMA Royalty Corporation and a wholly owned XOMA subsidiary. This filing details the structure of a tender offer for all outstanding shares of Generation Bio common stock, the subsequent merger in which Generation Bio would become a wholly owned subsidiary of XOMA Royalty, and the associated contingent value rights (CVRs). It also describes conditions to closing, treatment of equity awards, non-solicitation provisions, termination rights and the role of tender and support agreements with certain stockholders.
Through this filings page, users can access Generation Bio’s 8-Ks and other SEC documents as they become available from EDGAR. AI-powered tools on the platform can help summarize lengthy filings, highlight key terms in merger agreements, and surface information on topics such as transaction structure, listing status, compensation arrangements and financial reporting, enabling a more efficient review of GBIO’s regulatory disclosures.
Generation Bio (GBIO) filed a Form 4 indicating an executive transition. The reporting person, who served as Chief Operating Officer, will no longer hold that role effective October 31, 2025. As a result, she will no longer be subject to Section 16 reporting for transactions in Generation Bio equity.
This change means the insider will cease filing Forms 4 and 5 related to Generation Bio securities. The filing does not detail any share transactions in the provided excerpt.
Generation Bio Co. announced leadership changes. Geoff McDonough, M.D. will resign as Chief Executive Officer effective October 31, 2025, and will become chairman of the Board. Under a separation agreement, he will receive cash severance of approximately $700,000, a payment in lieu of bonus of approximately $300,000 for 2025, up to 12 months of healthcare coverage, and 25% acceleration of his outstanding unvested equity awards. He will also receive a $70,000 bonus related to the company’s strategic alternatives review.
The company plans to engage Dr. McDonough as a consultant through October 31, 2026 at $500 per hour, with continued equity vesting during consulting. The Board elected Yalonda Howze as Interim CEO and President, with a $575,000 base salary and a target bonus set at 50% of base, plus specified severance protections, including enhanced benefits upon a change in control. Consulting agreements are also expected with COO Antoinette Paone ($360/hour) and CSO Phillip Samayoa ($400/hour) through October 31, 2026, with continued equity vesting.
Generation Bio (GBIO) Chief Scientific Officer reported routine equity transactions on 10/15/2025. 114 shares of common stock were issued upon settlement of restricted stock units (code M), and 34 shares were withheld to cover taxes at $6.71 per share (code F). Following these transactions, the officer directly owned 14,138 common shares.
The filing notes a one-for-10 reverse stock split effected on July 21, 2025. The RSU grant from January 20, 2023 vests over four years; 573 RSUs remained beneficially owned after the reported activity.
Generation Bio (GBIO) President & CEO and Director reported Form 4 activity on 10/15/2025. The filing shows an M transaction converting 527 restricted stock units into common shares and an F transaction disposing of 155 shares at $6.71.
Following these transactions, the reporting person directly holds 136,836 common shares and indirectly holds 22,646 and 27,500 shares via the 2018 and 2020 family trusts, respectively. Derivative holdings include 2,636 RSUs. Amounts reflect the one-for-10 reverse stock split effective July 21, 2025.
Generation Bio (GBIO) reported an insider transaction by its Chief Legal Officer on October 15, 2025. The officer settled 334 shares of common stock upon the vesting/settlement of restricted stock units (code M). To cover taxes, 99 shares were withheld at $6.71 (code F).
Following these transactions, the officer directly owned 2,345 shares of common stock and held 2,008 restricted stock units. The filing notes amounts reflect the one-for-10 reverse stock split effected on July 21, 2025. The underlying RSU grant was 5,355 units from April 5, 2023, vesting 25% on April 15, 2024, with the remainder vesting in equal quarterly installments thereafter.
Generation Bio (GBIO) reported insider activity for its Chief Operating Officer on a Form 4. On 10/15/2025, 159 shares of common stock were acquired upon RSU vesting, and 47 shares were disposed at $6.71 to cover taxes. After these transactions, the officer directly owns 3,658 shares, with 795 RSUs remaining. The reported amounts reflect the issuer’s 1-for-10 reverse stock split effective 07/21/2025.
Generation Bio (GBIO) reported an insider transaction by its Chief Financial Officer on 10/15/2025. The filing shows 58 shares of common stock were acquired following the settlement of restricted stock units (Code M), and 18 shares were disposed of at $6.71 (Code F). Following these transactions, the officer directly owned 1,867 shares.
The report notes a one-for-10 reverse stock split effected on July 21, 2025. It also references a grant of 939 restricted stock units made on January 20, 2023, with 25% vested on January 15, 2024, and the remainder vesting in equal quarterly installments thereafter.
Generation Bio Co. furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is being furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The Form 8-K itself does not include any financial figures, metrics, or narrative of the results; readers must consult Exhibit 99.1 for the actual numbers and commentary.